Axogen, Inc. Common Stock
AXGNAxogen, Inc. is a biotechnology company focused on the development and commercialization of surgical grafts to repair, replace, or regenerate peripheral nerve tissue. The company specializes in products aimed at nerve repair and regeneration, providing solutions for nerve injuries resulting from surgery, trauma, and other conditions. Based in Florida, Axogen aims to improve functional outcomes for patients with nerve damage.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| February 12, 2010 | $1.00 | 2010-01-27 | 2010-01-29 |
| March 11, 2005 | $0.06 | 2005-02-23 | 2005-02-25 |
Dividends Summary
- Consistent Payer: Axogen, Inc. Common Stock has rewarded shareholders with 2 dividend payments over the past 5 years.
- Total Returned Value: Investors who held AXGN shares during this period received a total of $1.06 per share in dividend income.
- Latest Payout: The most recent dividend of $1.00/share was paid 6000 days ago, on February 12, 2010.
- Dividend Growth: Since 2005, the dividend payout has grown by 1566.7%, from $0.06 to $1.00.
Company News
Axogen, Inc. announced that management will participate in three investor conferences in March 2026: Raymond James 47th Annual Institutional Investors Conference (March 3), Leerink Global Healthcare Conference (March 9), and The Citizens Life Sciences Conference (March 10). The company will present and hold 1x1 investor meetings at these events, ...
Axogen, Inc. (Nasdaq: AXGN), a peripheral nerve repair solutions company, announced it will release its fourth quarter and full year 2025 financial results on February 24, 2026, followed by a management conference call and webcast at 8:00 a.m. ET. The company invites investors to participate via phone or live webcast.
Axogen, Inc. announced an upsized underwritten public offering of 4 million shares at $31.00 per share, expected to raise approximately $124 million in gross proceeds. The company plans to use the net proceeds to pay off its term loan facility with Oberland Capital, along with working capital and capital expenditures. The offering is expected to ...
Axogen reported preliminary full-year 2025 revenue of approximately $225.2 million, representing 20.2% growth over 2024, with Q4 2025 revenue expected at $59.9 million (21.3% increase). The company achieved FDA Biologics License Application approval for Avance® on December 3, 2025, and expects gross margins above 74%. Cash position improved by a...
Axogen received FDA Biologics License Application approval for AVANCE, an acellular nerve scaffold for treating peripheral nerve discontinuities in patients aged 1 month and older, with commercial availability expected in early Q2 2026.
